AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Xencor Inc. (XNCR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

15.85

-0.35 (-2.16%)

At close: Feb 20, 2025, 3:59 PM

15.79

-0.35%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	13.19
Market Cap	1.11B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.18
PE Ratio (ttm)	-4.98
Forward PE	n/a
Analyst	Buy

Ask	18.44
Volume	283,802
Avg. Volume (20D)	624,774
Open	16.16
Previous Close	16.20
Day's Range	15.56 - 16.22
52-Week Range	15.31 - 27.24
Beta	undefined

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with r...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 3, 2013

Employees 280

Stock Exchange NASDAQ

Ticker Symbol XNCR

Website https://www.xencor.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for XNCR stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 120.89% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Xencor Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

+10.45%

Xencor shares are trading higher. The company pric... Unlock content with Pro Subscription

5 months ago

+22.93%

Xencor shares are trading higher after the company announced four new XmAb programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs.

News

1 month ago · zacks.com

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...

1 month ago · zacks.com

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

1 month ago · zacks.com

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

1 month ago · zacks.com

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago · zacks.com

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 months ago · businesswire.com

Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today...

3 months ago · seekingalpha.com

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of...